Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Geron gets green light for human trial of ES cell–derived product

Nature Biotechnology volume 27, pages 213–214 (2009)Cite this article

This summer, Geron Corporation of Menlo Park, California, will begin treating ten patients who have suffered a complete thoracic-level spinal cord injury in a phase 1 multicenter trial. The pioneering therapy is Geron's 'GRNOPC1 product', which contains hES cell–derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth–stimulating properties.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Louisville, Colorado

    Joe Alper

Authors
  1. Joe Alper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Alper, J. Geron gets green light for human trial of ES cell–derived product. Nat Biotechnol 27, 213–214 (2009). https://doi.org/10.1038/nbt0309-213a

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0309-213a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing